Bank Vontobel AG Stock

Certificat

RMASBV

CH1283320989

Market Closed - Bid/Ask 11:20:00 2024-06-06 am EDT			After market 11:15:01 am
102.4 ^CHF	-1.06%		102.2	-0.20%

3 months	-1.73%
6 months	+2.09%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart ELI LILLY AND COMPANY

Latest news about ELI LILLY AND COMPANY

TRexBio Announces Collaboration Partner Lilly Has Initiated a Phase 1 Study of TRB-051 for Autoimmune and Inflammatory Diseases	08:32am	AQ
Augustine Therapeutics announces EUR17 million Series A1 financing round	08:32am	AQ
Augustine Therapeutics N.V. announced that it expects to receive funding from a group of investors	Jun. 25	CI
Top Midday Stories: Microsoft Hit with EU Antitrust Charges; Judge Blocks Swipe-Fee Settlement Between Visa, Mastercard and Retailers; Novo Nordisk Secures Chinese Approval for Weight-Loss Drug; Tesla, Ford Issue Recalls	Jun. 25	MT

More news

Static data

Product type	Reverse Convertibles
Buy / Sell	CALL
Underlying	ELI LILLY AND COMPANY
Issuer	Vontobel
	RMASBV
ISIN	CH1283320989
Date issued	2023-09-01
Strike	557.1 $
Maturity	2025-03-03 (249 Days)
Parity	1 : 1
Emission price	100 CHF
Emission volume	N/A
Settlement	both
Currency	CHF

Technical Indicators

Highest since issue	104.2 CHF
Lowest since issue	97.5 CHF
Spread	8 CHF
Spread %	0.78%

Company Profile

Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.5%); - immunology diseases (11.1%); - neurology (8.4%): primarily drugs used in treating depression and schizophrenia; - other (3.3%). Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).

Sector

More about the company